Dry-eye expert Allergan bets $125M on Oculeve and its new implant approach

Allergan ($AGN) is adding to its dry-eye lineup with a new purchase agreement. The company has bet $125 million on a new approach to the disease, picking up Oculeve and lead candidate OD-01--a nerve-stimulating implant placed in the nose. More from FierceBiotech

Suggested Articles

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.